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STATINS FOR PEOPLE AT LOW RISK
N-of-1 approach to determine when adverse effects
are caused by statins
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McPherson finds it shocking that a Cochrane review group is
not interested in seeking data on adverse events associated with
statins.1 If he read our Cochrane reviews on statins he would
see that findings related to adverse events are reported.2 What
is more shocking is that a systematic review of the adverse
effects of statins using observational and randomised trial
evidence that we submitted to The BMJ was rejected without
review. The reviewwas published and concluded: “The absolute
excess risk of the observed harmful unintended effects of statins
is very small compared to the beneficial effects of statins on
major cardiovascular events.”3 Perhaps these findings did not
chime well with The BMJ’s editors, who have taken a stand
against widespread use of statins.
Doctors and patients often attribute adverse effects to statins,
but the evidence we have from trials indicates that “Only a small
minority of symptoms reported on statins are genuinely due to
the statins: almost all would occur just as frequently on
placebo.”4 The Cholesterol Treatment Trialists’ (CTT)
collaboration has developed a detailed protocol for collecting
all relevant data from trials for a definitive study of the adverse
effects of statins. CTT has engaged with a wide range of
collaborators, including the Cochrane Heart Group, in setting
up this new study.
This work will take some time to complete. In the meantime,
further evidence is available from n-of-1 trials in which eight
patients who had experienced myalgia symptoms while taking
statins were randomly and blindly swapped between placebo
and statin over repeat three week periods.5 The frequency and
severity of symptomswere indistinguishable when these patients
were taking statins or placebo, making it unlikely that statins
were causal. The authors suggested that doctors might find it
helpful to use an n-of-1 approach to determine which patients’
adverse effects are caused by statins, a view with which we
concur.
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